Jasmine I. Rizzo
- Oncology top 2%
- Immunology top 5%
- Molecular Biology
- Pulmonary and Respiratory Medicine top 10%
- Cancer Research
- Co-authors
- F. Stephen HodiJames LarkinDirk SchadendorfJedd D. WolchokChristopher D. LaoMichael SmylieVanna Chiarion‐SileniReinhard Dummer
- Topics
- Cancer Immunotherapy and Biomarkers (12 papers)CAR-T cell therapy research (9 papers)Melanoma and MAPK Pathways (6 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Jasmine I. Rizzo
18 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Oncology 1.1k
- Immunology 465
- Molecular Biology 382
- Pulmonary and Respiratory Medicine 239
- Cancer Research 91
Countries citing papers authored by Jasmine I. Rizzo
This map shows the geographic impact of Jasmine I. Rizzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasmine I. Rizzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasmine I. Rizzo more than expected).
Fields of papers citing papers by Jasmine I. Rizzo
This network shows the impact of papers produced by Jasmine I. Rizzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasmine I. Rizzo. The network helps show where Jasmine I. Rizzo may publish in the future.
Co-authorship network of co-authors of Jasmine I. Rizzo
This figure shows the co-authorship network connecting the top 25 collaborators of Jasmine I. Rizzo. A scholar is included among the top collaborators of Jasmine I. Rizzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasmine I. Rizzo. Jasmine I. Rizzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 76 | |
| 4 | 12 | |
| 5 | 1 | |
| 6 | 2 | |
| 7 | 2 | |
| 8 | 41 | |
| 9 | 4 | |
| 10 | 1 | |
| 11 | 28 | |
| 12 | 14 | |
| 13 | 15 | |
| 14 | 56 | |
| 15 | 1 | |
| 16 | 1 | |
| 17 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialbreakdown → | 1009 |
| 18 | 3 |
About Jasmine I. Rizzo
Jasmine I. Rizzo is a scholar working on Oncology, Cancer Research and Immunology, having authored 18 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (9 papers) and Melanoma and MAPK Pathways (6 papers). The work is most often cited by research in Oncology (1.1k citations), Immunology (465 citations) and Pulmonary and Respiratory Medicine (239 citations). Jasmine I. Rizzo has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include F. Stephen Hodi, James Larkin, Dirk Schadendorf, Jedd D. Wolchok, Christopher D. Lao, Michael Smylie, Vanna Chiarion‐Sileni, Reinhard Dummer, Pier Francesco Ferrucci and Iván Márquez‐Rodas. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.